Public Citizen's Health Research Group

Ulf Jonasson
Doctor of Public Health,
Nordic School of Public Health, Gothenburg, Sweden
ulf.jonasson@wtnord.se

Birgitta Jonasson PhD,
Department of Forensic Medicine, University of Uppsala, Sweden

ENDNOTES

[1] The top 200 generic drugs in 2004 (by units and by retail dollars). Drugtopics.com [online]. Using IMS data from December 2005, four companies (Teva, Mylan, Mallinckrodt, and QLT) out of a total of 13 selling propoxyphene-containing products, sold 91% of the 2.15 million prescriptions that month, with two, Teva and QLT accounting for 54% of the 2.15 million prescriptions filled that month.

[2] Substance Abuse and Mental Health Services Administration: Office of Applied Studies. Drug Abuse Warning Network Annual Medical Data 1999.

[3] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med Jul 1997;151:1531-36.

[4] Won AB, Lapane KL, Vallow S, Schein J, Morris JN, Lipsitz LA. Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc. 2004 Jun;52(6):867-74.

[5] Li Wan Po A, Zhang WY. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to acetaminophen. BMJ. 1997 Dec 13;315(7122):1565-71.

[6] Kamal-Bahl S, Stuart BC, Beers MH. National Trends and Predictors of Propoxyphene Use in Community-Dwelling Elderly. Am J Geriatr Pharmacother 2005;3:186-95.

[7] Simon SR, Chan KA, Soumerai SB, Wagner AK, Andrade SE, Feldstein AC, Lafata JE, Davis RL, Gurwitz JH. Potentially inappropriate medication use by elderly persons in U.S. Health Maintenance Organizations, 2000-2001. Am Geriatr Soc.2005 Feb;53(2):227-32.

[8] Caterino JM, Emond JA, Camargo CA Jr. Inappropriate medication administration to the acutely ill elderly: a nationwide emergency department study, 1992-2000. J Am Geriatr Soc. 2004 Nov;52(11):1847-55.

[9] Kamal-Bahl SJ, Doshi JA, Stuart BC, Briesacher BA. Propoxyphene use by community-dwelling and institutionalized elderly Medicare beneficiaries. J Am Geriatr Soc.2003 Aug;51(8):1099-104.

[10] Perri M 3rd, Menon AM, Deshpande AD, Shinde SB, Jiang R, Cooper JW, Cook CL, Griffin SC, Lorys RA. Adverse outcomes associated with inappropriate drug use in nursing homes. Ann Pharmacother .2005 Mar;39(3):405-11.

[11] HEW Quarterly Report on Propoxyphene, Third Quarter 1978 – Fourth Quarter 1979, p. 2.

[12] DEA, Compliance Survey Regarding Propoxyphene," to the FDA, US Department of Justice, Washington DC, March 20, 1979, p. 5.

[13] Morris L. Memorandum on the Lilly Quarterly Report on Darvon, to the Director of the Division of Drug Experience. February 5, 1980.

[14] The top 200 generic drugs in 2004 (by units). Drugtopics.com [online]. Mar 22, 2003.

[15] Collins SL, Edwards JE, Moore RA, McQuay HJ. Single dose dextropropoxyphene, alone and with paracetamol (acetaminophen), for postoperative pain. Cochrane Database Syst Rev. 2000;(2):CD001440.

[16] Hopkinson JH 3rd, Blatt G, Cooper M. Effective pain relief: comparative results with acetaminophen in a new dose formulation, propoxyphene napsylate-acetaminophen combination, and placebo. Curr Ther Res Clin Exp. 1976 Jun; 19(6): 622-630.

[17] Miller RR, et al.. Propoxyphene hydrochloride: a critical review. JAMA. 1970; 213(6): 996-1006.

[18] Miller RR, et al.. Propoxyphene hydrochloride: a critical review. JAMA. 1970; 213(6): 996-1006.

[19] Li Wan Po A, Zhang WY. Systematic overview of co-proxamol to assess analgesic effects of addition of dextropropoxyphene to paracetamol. BMJ. 1997 Dec 13;315(7122):1565-71.

[20] Hanks GW, Forbes K. Co-proxamol is effective in chronic pain. BMJ. 1998; Jun 27;316(7149):1980.

[21] Moertel CG. Testimony before the Select Committee on Small Business, U.S. Senate, in Competitive Problems in the Drug Industry, Part 34, U.S. Government, Washington DC, 1979, pp. 16641 and 16642.

2006P-0090

SUP 2

6/20/2006 2:24 PM

[22] Whitcomb DC, Gilliam FR 3rd, Starmer CF, Grant AO. Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine. J. Clin. Invest. 1989; 84: 1629-36.

[23] Mortality data from the Drug Abuse Warning Network. 1981-2002.

[24] Verebeley K, Inturrisi CE. The simultaneous determination of propoxyphene and norpropoxyphene in human biofluids using gas liquid chromatography. J of Chrom. 1973; 75: 195-205.

[25] Baselt RC. Forensic toxicology of propoxyphene fatalities. Testimony before FDA, April 6, 1979, p. 4.

[26] Henry JA, Cassidy SL. Membrane stabilizing activity: a major cause of fatal poisoning. Lancet. 1986, i: 1414-7.

[27] Whitcomb DC, Gilliam FR 3rd, Starmer CF, Grant AO. Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine. J. Clin. Invest. 1989; 84: 1629-36.

[28] Afshari R, Bateman DN. ECG abnormalities in co-proxamol (paracetamol / dextropropoxyphene) poisoning. Journal of Toxicology: Clinical Toxicology. 2003; 41: 560.

[29] Inturrisi CE. Personal communication to Dr. Sidney M. Wolfe. January 29, 1979.

[30] Gorodetsky C. Personal communication to Dr. Sidney M. Wolfe. February 8, 1979.

[31] Verebeley K, Inturrisi CE. The simultaneous determination of propoxyphene and norpropoxyphene in human biofluids using gas liquid chromatography. J of Chrom. 1973; 75: 195-205.

[32] Christensen H. Dextropropoxyphene and norpropoxyphene in blood, muscle, liver, and urine in fatal poisoning. Acta Permacol et Toxicol. 1977; 40: 298-209.

[33] Lund-Jacobsen H. Cardio-respiratory toxicity of propoxyphene and norpropoxyphene in conscious rabbits. Acta Pharmacol et Toxicol. 1978; 42: 171-178.

[34] Toxicology Tutor I: Glossary. http://www.sis.nim.nih.gov/ToxTutor/Tox1/glossm.htm [online].

[35] Young RJ, Lawson AAH. Distalgesic poisoning: cause for concern. BMJ. 1980. 280: 1045-7.

[36] Whittington RM. Dextropropoxyphene deaths: coroner's report. Hum Toxicol. 1984: 3(suppl): 1755-85S

[37] Obafunwa JO, Busuttil A, al-Oqleh AM. Dextropropoxyphene-related deaths--a problem that persists? Int J Legal Med. 1994;106(6):315-8.

[38] Koski A, Ojanpera I, Vuori E. Interactions of alcohol and drugs in fatal poisonings. Hum Exp Toxicol. 2003; 22(5): 281-287

[39] Jonasson U, Jonasson B, Saldeen T. Middle-aged men – a risk category regarding fatal poisoning due to dextropropoxyphene and alcohol in combination. Preventive Medicine. 2000 Aug;31(2 Pt 1):103-6.

[40] Jonasson B, Jonasson U, Saldeen T. Suicides may be overreported and accidents underreported among fatalities due to dextropropoxyphene. J Forensic Sci. 1999 Mar;44(2):334-8.

[41] Jonasson U, Jonasson B, Saldeen T. Middle-aged men – a risk category regarding fatal poisoning due to dextropropoxyphene and alcohol in combination. Preventive Medicine. 2000 Aug;31(2 Pt 1):103-6.

[42] Jaffe JH, Martin WR. 1980. Opioid agonists and antagonists. *In* The Pharmacological Basis of Therapeutics. AG Gilman LS Goodman and A Gilman, editors. McMillan Publishing Co., Inc., New York. 479-534.

[43] Hawton K, Simkin S, Deeks J. Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings. BMJ. 2003 May 10;326(7397):1006-8.

[44] Hawton K, Simkin S, Deeks J. Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings. BMJ. 2003 May 10;326(7397):1006-8.

[45] Druid H, Holmgren. A complilation of fatal and control concentrations of drugs in postmortem femoral blood. J Forensic Sci. 1997; 42: 79-87.

[46] Jonsson A, Holmgren P, Ahlner J. Fatal intoxications in a Swedish forensic autopsy material during 1992-2002. Forensic Sci Int. 2004 Jun 30;143(1):53-9.

[47] The top 200 generic drugs in 2004 (by units). Drugtopics.com [online]. Mar 22, 2003.

[48] Mortality data from the Drug Abuse Warning Network. 1981-2002.

[49] Jonsson A, Holmgren P, Ahlner J. Fatal intoxications in a Swedish forensic autopsy material during 1992-2002. Forensic Sci Int. 2004 Jun 30;143(1):53-9.

[50] Welsh TS, Kaplan J. The Role of post-mortem examination in medical education. 1998 Aug;73(8): 802-805.

[51] Sinard JH. Factors affecting autopsy rates, autopsy request rates, and autopsy findings at a large academic medical center. Exp Mol Pathol. 2001 Jun;70(3):333-43.

[52] Katz PR, Seidel G. Nursing home autopsies. Survey of physician attitudes and practice patterns. Arch Pathol Lab Med. 1990 Feb;114(2):145-7.

[53] Won AB, Lapane KL, Vallow S, Schein J, Morris JN, Lipsitz LA. Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc. 2004 Jun;52(6):867-74.

[54] Inturrisi CE. Personal communication to Dr. Sidney M. Wolfe. January 29, 1979.

[55] Furman RH, in response to a question by Congressman Leland during Congressional hearings on Darvon, May 21, 1980.

[56] Reproduced from the Institute of Medicine Report of a Study: Sleeping Pills, Insomnia, and Medical Practice. NAS 1979, p. 66.

[57] Flanagan RJ, Johnston A, White AS, Crome P. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage. Br J Clin Pharmacol. 1989 Oct;28(4):463-9.

[58] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for determining potentially inappropriate medication use by the elderly. Arch Intern Med Jul 1997;151:1531-36.

[59] Kamal-Bahl SJ, Doshi JA, Stuart BC, Briesacher BA. Propoxyphene use by community-dwelling and institutionalized eldlerly medicare beneficiaries. J Am Geriatr Soc. 2003; Aug 51(8):1099-1104.

[60] Won AB, Lapane KL, Vallow S, Schein J, Morris JN, Lipsitz LA. Persistent nonmalignant pain and analgesic prescribing patterns in elderly nursing home residents. J Am Geriatr Soc. 2004; Jun;52(6):867-74.

[61] Cass LJ et al. Physical Dependence Potentiality of Analgesics. Curr. Ther. Res. Clin. Exp. 1961; 3:289-299.

[62] US Justice Department. A study of the abuse potential of dextropropoxyphene with control recommendations. January 1976, pp. 57-64.

[63] Fraser HF, Isbell H. Pharmacology and Addiction Liability of dl- and d-propoxyphene. Bull Narc. 1960; 12: 9-14.

[64] Farley EC, Santo Y. The Abuse of Darvon in a National Sample of Adolescents Admitted to Drug Abuse Treatment Programs. Philadelphia Psychiatric Center, unpublished.

[65] O'Donnell JA et al. Young men and drugs: a nation-wide survey. NIDA, 1976.

[66] Ng B, Alvear M. Dextropropoxyphene addiction--a drug of primary abuse. Am J Drug Alcohol Abuse. 1993;19(2):153-8.

[67] Trends in Drug-Related Emergency Department Visits, 1994-2002 At a Glance. Drug Abuse Warning Network (DAWN). November 2003